GNRH1 and uterine corpus leiomyoma: A clinical trial comparing ulipristal given at doses of either 5 or 10 mg daily to patients with symptomatic uterine fibroids before surgery against a once-a-month injection of the gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate used as a standard of care demonstrated similarities with the approaches in controlling uterine bleeding, with the advantage that ulipristal-treated patients were less likely to have hot flashes, very commonly induced by GnRH agonists due to suppression of E2 (Donnez et al. 2012).